1. Pink Sheet
  2. >>Geography
  3. >>Europe

Europe Must Not Squander Potential Of Reformulation

Pharmanovia And Medicines For Europe Executive Makes Case For Inclusion In Legislation

 
• By Dave Wallace

At a panel on value added medicines at Medicines for Europe’s 30th annual conference in Dublin, Pharmanovia CEO and value added medicines sector chair James Burt set out the case for expanding the scope of current EU pharma legislation proposals to reward reformulation alongside repurposing.

James Burt speaks at Value Added Medicines panel, Medicines for Europe conference
James Burt talks about value added medicines at a conference panel • Source: Medicines for Europe

EU efforts to incentivize value added medicines – products that innovate around existing known molecules – are welcome, but do not go far enough. That was the message that came through at Medicines for Europe’s 30th annual conference in Dublin last month, where delegates heard that Europe could risk missing out on the benefits of reformulated medicines by focusing solely on incentivizing repurposing drugs with new indications.

Legislative efforts to recognize the value of repurposed medicines, set out in directive Article 84 of the EU’s new proposed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 
• By Neena Brizmohun

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 
• By Francesca Bruce

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.

More from Generics Bulletin

Formycon And Fresenius Launch Partnered Stelara Rival In Canada

 
• By Adam Zamecnik

Several years after the initial signing of their agreement, Formycon and Fresenius Kabi announced the launch of their Stelara biosimilar Otulfi in Canada, adding another key market to their list.

Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’

 
• By Dean Rudge

A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.

Biocon To Launch Approved Generic Liraglutide ‘Expeditiously’ In India

 
• By Urtė Fultinavičiūtė

Marking its first vertically integrated GLP-1 product in India, Biocon said the generic liraglutide was approved under CDSCO’s Rule 101, which recognizes approvals from “established and referenced serious regulatory authorities.”